Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use.

Chen KTJ, Anantha M, Leung AWY, Kulkarni JA, Militao GGC, Wehbe M, Sutherland B, Cullis PR, Bally MB.

Drug Deliv Transl Res. 2019 Sep 3. doi: 10.1007/s13346-019-00674-7. [Epub ahead of print]

PMID:
31482519
2.

Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia.

Chen KTJ, Gilabert-Oriol R, Bally MB, Leung AWY.

Pharm Res. 2019 Jun 24;36(9):125. doi: 10.1007/s11095-019-2654-z. Review.

3.

Liposomal OTS964, a TOPK inhibitor: a simple method to estimate OTS964 association with liposomes that relies on enhanced OTS964 fluorescence when bound to albumin.

Gilabert-Oriol R, Sutherland BW, Anantha M, Pallaoro A, Bally MB.

Drug Deliv Transl Res. 2019 Jun 17. doi: 10.1007/s13346-019-00651-0. [Epub ahead of print]

PMID:
31209826
4.

What Drives Innovation: The Canadian Touch on Liposomal Therapeutics.

Leung AWY, Amador C, Wang LC, Mody UV, Bally MB.

Pharmaceutics. 2019 Mar 16;11(3). pii: E124. doi: 10.3390/pharmaceutics11030124. Review.

5.

Liposomal formulations of carboplatin injected by convection-enhanced delivery increases the median survival time of F98 glioma bearing rats.

Shi M, Anantha M, Wehbe M, Bally MB, Fortin D, Roy LO, Charest G, Richer M, Paquette B, Sanche L.

J Nanobiotechnology. 2018 Oct 5;16(1):77. doi: 10.1186/s12951-018-0404-8.

6.

Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response.

Gilabert-Oriol R, Ryan GM, Leung AWY, Firmino NS, Bennewith KL, Bally MB.

Int J Mol Sci. 2018 Sep 26;19(10). pii: E2922. doi: 10.3390/ijms19102922. Review.

7.

Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.

Wang Y, Chen SY, Colborne S, Lambert G, Shin CY, Santos ND, Orlando KA, Lang JD, Hendricks WPD, Bally MB, Karnezis AN, Hass R, Underhill TM, Morin GB, Trent JM, Weissman BE, Huntsman DG.

Mol Cancer Ther. 2018 Dec;17(12):2767-2779. doi: 10.1158/1535-7163.MCT-18-0348. Epub 2018 Sep 19.

PMID:
30232145
8.

Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor.

Leung AWY, Anantha M, Dragowska WH, Wehbe M, Bally MB.

J Control Release. 2018 Sep 28;286:1-9. doi: 10.1016/j.jconrel.2018.07.025. Epub 2018 Jul 18.

9.

Transition Metal Ions Promote the Bioavailability of Hydrophobic Therapeutics: Cu and Zn Interactions with RNA Polymerase I Inhibitor CX5461.

Prosser KE, Leung AWY, Harrypersad S, Lewis AR, Bally MB, Walsby CJ.

Chemistry. 2018 Apr 25;24(24):6334-6338. doi: 10.1002/chem.201800289. Epub 2018 Apr 6.

PMID:
29490115
10.

Development of a copper-clioquinol formulation suitable for intravenous use.

Wehbe M, Malhotra AK, Anantha M, Lo C, Dragowska WH, Dos Santos N, Bally MB.

Drug Deliv Transl Res. 2018 Feb;8(1):239-251. doi: 10.1007/s13346-017-0455-7.

11.

In Vivo Validation of PAPSS1 (3'-phosphoadenosine 5'-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target.

Leung AWY, Veinotte CJ, Melong N, Oh MH, Chen K, Enfield KSS, Backstrom I, Warburton C, Yapp D, Berman JN, Bally MB, Lockwood WW.

Clin Cancer Res. 2017 Nov 1;23(21):6555-6566. doi: 10.1158/1078-0432.CCR-17-0700. Epub 2017 Aug 8.

12.

Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status.

Wehbe M, Lo C, Leung AWY, Dragowska WH, Ryan GM, Bally MB.

Invest New Drugs. 2017 Dec;35(6):682-690. doi: 10.1007/s10637-017-0488-2. Epub 2017 Jul 21.

13.

A Perspective - can copper complexes be developed as a novel class of therapeutics?

Wehbe M, Leung AWY, Abrams MJ, Orvig C, Bally MB.

Dalton Trans. 2017 Aug 22;46(33):10758-10773. doi: 10.1039/c7dt01955f. Review.

PMID:
28702645
14.

Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent.

Wehbe M, Anantha M, Shi M, Leung AW, Dragowska WH, Sanche L, Bally MB.

Int J Nanomedicine. 2017 May 31;12:4129-4146. doi: 10.2147/IJN.S137347. eCollection 2017.

15.

Optimization of liposomal topotecan for use in treating neuroblastoma.

Chernov L, Deyell RJ, Anantha M, Dos Santos N, Gilabert-Oriol R, Bally MB.

Cancer Med. 2017 Jun;6(6):1240-1254. doi: 10.1002/cam4.1083. Epub 2017 May 23.

16.

Unique therapeutic properties and preparation methodology of multivalent rituximab-lipid nanoparticles.

Popov J, Gilabert-Oriol R, Bally MB.

Eur J Pharm Biopharm. 2017 Aug;117:256-269. doi: 10.1016/j.ejpb.2017.04.024. Epub 2017 Apr 24.

PMID:
28450189
17.

The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.

Wang Y, Chen SY, Karnezis AN, Colborne S, Santos ND, Lang JD, Hendricks WP, Orlando KA, Yap D, Kommoss F, Bally MB, Morin GB, Trent JM, Weissman BE, Huntsman DG.

J Pathol. 2017 Jul;242(3):371-383. doi: 10.1002/path.4912. Epub 2017 Jun 2.

PMID:
28444909
18.

In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.

Gilabert-Oriol R, Chernov L, Anantha M, Dragowska WH, Bally MB.

Drug Deliv Transl Res. 2017 Aug;7(4):544-557. doi: 10.1007/s13346-017-0380-9.

PMID:
28432657
19.

Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity.

Baradaran-Heravi A, Niesser J, Balgi AD, Choi K, Zimmerman C, South AP, Anderson HJ, Strynadka NC, Bally MB, Roberge M.

Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3479-3484. doi: 10.1073/pnas.1620982114. Epub 2017 Mar 13. Retraction in: Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11885.

20.

A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.

Wehbe M, Malhotra A, Anantha M, Roosendaal J, Leung AWY, Plackett D, Edwards K, Gilabert-Oriol R, Bally MB.

J Control Release. 2017 Apr 28;252:50-61. doi: 10.1016/j.jconrel.2017.03.010. Epub 2017 Mar 10.

21.

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.

Xu H, Di Antonio M, McKinney S, Mathew V, Ho B, O'Neil NJ, Santos ND, Silvester J, Wei V, Garcia J, Kabeer F, Lai D, Soriano P, Banáth J, Chiu DS, Yap D, Le DD, Ye FB, Zhang A, Thu K, Soong J, Lin SC, Tsai AH, Osako T, Algara T, Saunders DN, Wong J, Xian J, Bally MB, Brenton JD, Brown GW, Shah SP, Cescon D, Mak TW, Caldas C, Stirling PC, Hieter P, Balasubramanian S, Aparicio S.

Nat Commun. 2017 Feb 17;8:14432. doi: 10.1038/ncomms14432.

22.

Mastoparan is a membranolytic anti-cancer peptide that works synergistically with gemcitabine in a mouse model of mammary carcinoma.

Hilchie AL, Sharon AJ, Haney EF, Hoskin DW, Bally MB, Franco OL, Corcoran JA, Hancock REW.

Biochim Biophys Acta. 2016 Dec;1858(12):3195-3204. doi: 10.1016/j.bbamem.2016.09.021. Epub 2016 Oct 18.

23.

Synthetic lethality in lung cancer and translation to clinical therapies.

Leung AW, de Silva T, Bally MB, Lockwood WW.

Mol Cancer. 2016 Sep 29;15(1):61. Review.

24.

Identification of breast cancer cell subtypes sensitive to ATG4B inhibition.

Bortnik S, Choutka C, Horlings HM, Leung S, Baker JH, Lebovitz C, Dragowska WH, Go NE, Bally MB, Minchinton AI, Gelmon KA, Gorski SM.

Oncotarget. 2016 Oct 11;7(41):66970-66988. doi: 10.18632/oncotarget.11408.

25.

Sulfonation, an underexploited area: from skeletal development to infectious diseases and cancer.

Leung AW, Backstrom I, Bally MB.

Oncotarget. 2016 Aug 23;7(34):55811-55827. doi: 10.18632/oncotarget.10046. Review.

26.

PRCosomes: pretty reactive complexes formed in liposomes.

Wehbe M, Chernov L, Chen K, Bally MB.

J Drug Target. 2016 Nov;24(9):787-796. Epub 2016 May 22. Review.

PMID:
27145072
27.

CF3 Derivatives of the Anticancer Ru(III) Complexes KP1019, NKP-1339, and Their Imidazole and Pyridine Analogues Show Enhanced Lipophilicity, Albumin Interactions, and Cytotoxicity.

Chang SW, Lewis AR, Prosser KE, Thompson JR, Gladkikh M, Bally MB, Warren JJ, Walsby CJ.

Inorg Chem. 2016 May 16;55(10):4850-63. doi: 10.1021/acs.inorgchem.6b00359. Epub 2016 May 4.

PMID:
27143338
28.

Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical Development.

Wehbe M, Anantha M, Backstrom I, Leung A, Chen K, Malhotra A, Edwards K, Bally MB.

PLoS One. 2016 Apr 7;11(4):e0153416. doi: 10.1371/journal.pone.0153416. eCollection 2016.

29.

Combined Use of Gene Expression Modeling and siRNA Screening Identifies Genes and Pathways Which Enhance the Activity of Cisplatin When Added at No Effect Levels to Non-Small Cell Lung Cancer Cells In Vitro.

Leung AW, Hung SS, Backstrom I, Ricaurte D, Kwok B, Poon S, McKinney S, Segovia R, Rawji J, Qadir MA, Aparicio S, Stirling PC, Steidl C, Bally MB.

PLoS One. 2016 Mar 3;11(3):e0150675. doi: 10.1371/journal.pone.0150675. eCollection 2016.

30.

Overexpression of HER-2 in MDA-MB-435/LCC6 Tumours is Associated with Higher Metabolic Activity and Lower Energy Stress.

Dragowska WH, Ginj M, Kozlowski P, Yung A, Ruth TJ, Adam MJ, Sossi V, Bally MB, Yapp DT.

Sci Rep. 2016 Jan 4;6:18537. doi: 10.1038/srep18537.

31.

Induction of Cytotoxicity in Pyridine Analogues of the Anti-metastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization.

Mu C, Chang SW, Prosser KE, Leung AW, Santacruz S, Jang T, Thompson JR, Yapp DT, Warren JJ, Bally MB, Beischlag TV, Walsby CJ.

Inorg Chem. 2016 Jan 4;55(1):177-90. doi: 10.1021/acs.inorgchem.5b02109. Epub 2015 Dec 11.

PMID:
26652771
32.

Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.

Verreault M, Wehbe M, Strutt D, Masin D, Anantha M, Walker D, Chu F, Backstrom I, Kalra J, Waterhouse D, Yapp DT, Bally MB.

J Control Release. 2015 Dec 28;220(Pt A):348-357. doi: 10.1016/j.jconrel.2015.10.053. Epub 2015 Nov 1.

PMID:
26528901
33.

3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents.

Leung AW, Dragowska WH, Ricaurte D, Kwok B, Mathew V, Roosendaal J, Ahluwalia A, Warburton C, Laskin JJ, Stirling PC, Qadir MA, Bally MB.

Oncotarget. 2015 Jul 10;6(19):17161-77.

35.

Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.

Neijzen R, Wong MQ, Gill N, Wang H, Karim T, Anantha M, Strutt D, Waterhouse D, Bally MB, Tai IT, Ng SS, Yapp DT.

J Control Release. 2015 Feb 10;199:72-83. doi: 10.1016/j.jconrel.2014.11.031. Epub 2014 Dec 8.

PMID:
25497312
36.

Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.

Waterhouse DN, Sutherland BW, Santos ND, Masin D, Osooly M, Strutt D, Ostlund C, Anantha M, Harasym N, Manisali I, Wehbe M, Bally MB, Webb MS.

Invest New Drugs. 2014 Dec;32(6):1071-82. doi: 10.1007/s10637-014-0138-x. Epub 2014 Jul 27.

37.

Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments.

Leung AW, Kalra J, Santos ND, Bally MB, Anglesio MS.

Nanomedicine (Lond). 2014 Mar;9(3):501-22. doi: 10.2217/nnm.13.220. Review.

PMID:
24746193
38.

Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.

Chittaranjan S, Bortnik S, Dragowska WH, Xu J, Abeysundara N, Leung A, Go NE, DeVorkin L, Weppler SA, Gelmon K, Yapp DT, Bally MB, Gorski SM.

Clin Cancer Res. 2014 Jun 15;20(12):3159-73. doi: 10.1158/1078-0432.CCR-13-2060. Epub 2014 Apr 10.

39.

Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer.

Dragowska WH, Weppler SA, Wang JC, Wong LY, Kapanen AI, Rawji JS, Warburton C, Qadir MA, Donohue E, Roberge M, Gorski SM, Gelmon KA, Bally MB.

PLoS One. 2013 Oct 11;8(10):e76503. doi: 10.1371/journal.pone.0076503. eCollection 2013.

40.

Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.

Hare JI, Neijzen RW, Anantha M, Dos Santos N, Harasym N, Webb MS, Allen TM, Bally MB, Waterhouse DN.

PLoS One. 2013 Apr 23;8(4):e62349. doi: 10.1371/journal.pone.0062349. Print 2013.

41.

Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model.

Verreault M, Weppler SA, Stegeman A, Warburton C, Strutt D, Masin D, Bally MB.

PLoS One. 2013;8(3):e59597. doi: 10.1371/journal.pone.0059597. Epub 2013 Mar 15.

42.

Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo.

Ahn RW, Barrett SL, Raja MR, Jozefik JK, Spaho L, Chen H, Bally MB, Mazar AP, Avram MJ, Winter JN, Gordon LI, Shea LD, O'Halloran TV, Woodruff TK.

PLoS One. 2013;8(3):e58491. doi: 10.1371/journal.pone.0058491. Epub 2013 Mar 20.

43.

Topotecan and doxorubicin combination to treat recurrent ovarian cancer: the influence of drug exposure time and delivery systems to achieve optimum therapeutic activity.

Patankar NA, Pritchard J, van Grinsven M, Osooly M, Bally MB.

Clin Cancer Res. 2013 Feb 15;19(4):865-77. doi: 10.1158/1078-0432.CCR-12-2459. Epub 2013 Jan 9.

44.

Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.

Patankar NA, Waterhouse D, Strutt D, Anantha M, Bally MB.

Invest New Drugs. 2013 Feb;31(1):46-58. doi: 10.1007/s10637-012-9832-8. Epub 2012 May 22.

PMID:
22615060
45.

A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer.

Musende AG, Eberding A, Wood CA, Adomat H, Fazli L, Hurtado-Coll A, Jia W, Bally MB, Tomlinson Guns ES.

Anticancer Drugs. 2012 Jun;23(5):543-52. doi: 10.1097/CAD.0b013e32835006f5.

PMID:
22481061
46.

Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy.

Waterhouse DN, Yapp D, Verreault M, Anantha M, Sutherland B, Bally MB.

Nanomedicine (Lond). 2011 Nov;6(9):1645-54. doi: 10.2217/nnm.11.140.

PMID:
22077466
47.

Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and in vivo activity.

Popov J, Kapanen AI, Turner C, Ng R, Tucker C, Chiu G, Klasa R, Bally MB, Chikh G.

Nanomedicine (Lond). 2011 Nov;6(9):1575-91. doi: 10.2217/nnm.11.50. Epub 2011 Oct 20.

PMID:
22011314
48.

Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.

Verreault M, Strutt D, Masin D, Anantha M, Waterhouse D, Yapp DT, Bally MB.

J Control Release. 2012 Feb 28;158(1):34-43. doi: 10.1016/j.jconrel.2011.09.095. Epub 2011 Oct 5.

PMID:
22001870
49.

The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.

Dragowska WH, Weppler SA, Qadir MA, Wong LY, Franssen Y, Baker JH, Kapanen AI, Kierkels GJ, Masin D, Minchinton AI, Gelmon KA, Bally MB.

BMC Cancer. 2011 Oct 1;11:420. doi: 10.1186/1471-2407-11-420.

50.

Development of glioblastoma cell lines expressing red fluorescence for non-invasive live imaging of intracranial tumors.

Verreault M, Strutt D, Masin D, Fink D, Gill R, Bally MB.

Anticancer Res. 2011 Jun;31(6):2161-71.

PMID:
21737636

Supplemental Content

Loading ...
Support Center